Roche Holding AG





Market Closed - Swiss Exchange 11:31:18 2024-07-19 am EDT 5-day change 1st Jan Change
278.3 CHF -0.04% Intraday chart for Roche Holding AG +9.22% +13.82%
LockThis Alphavalue article, the European leader in independent research, is only available to subscribers .
Alphavalue is exclusively on MarketScreener.
To unlock the article, SUBSCRIBE!
Already a customer? Log In
Swiss Market Index Slides; Schindler Edges Down MT
UK's Competition Watchdog Approves Roche's Purchase of LumiraDx Assets MT
Roche: positive two-year data for Susvimo CF
New Data for Roche?s Susvimo Demonstrates Sustained Efficacy in Two Serious Diabetic Eye Conditions CI
Health Care Climbs as J&J Rallies - Health Care Roundup DJ
ROCHE HOLDING : Obesity could lead Roche’s redemption journey Alphavalue
Global markets live: Adidas, TSMC, Vale, HSBC, J&J... Our Logo
Roche: results of a treatment for DME CF
Roche's Diabetic Macular Edema Therapy Demonstrates Efficacy, Safety in ExtensionStudy MT
Swiss Stocks Close Higher as Eurozone Inflation Eases MT
Genentech's Vabysmo Showed Extended Durability, Continued Efficacy and A Consistent Safety Profile in Long-Term Diabetic Macular Edema Study CI
Roche Obesity Pill Achieves Positive Results in Early-Stage Trial -- 3rd Update DJ
ROCHE HOLDINGS AG : Jefferies remains Neutral ZD
Wall Street set to fall as megacap chip, tech stocks tumble RE
ROCHE HOLDINGS AG : JP Morgan reaffirms its Sell rating ZD
North American Morning Briefing: Tech Lower Again as Rotation Continues DJ
Roche Obesity Pill Achieves Positive Results in Early-Stage Trial -- 2nd Update DJ
European shares slide as tech stocks weigh RE
ROCHE HOLDINGS AG : Goldman Sachs reiterates its Sell rating ZD
Roche: share price rises following successful obesity trial CF
Roche Obesity Pill Achieves Positive Results in Early-Stage Trial -- Update DJ
Roche reports positive early results in obesity drug trial RE
Roche Obesity Pill Achieves Positive Results in Early-Stage Trial DJ
Roche's Obesity Drug Lowers Weight in Early-stage Study MT
Roche Holding AG Announces Positive Phase I Results of Its Oral GLP-1 Receptor Agonist CT-996 for the Treatment of People with Obesity CI
Chart Roche Holding AG
More charts
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
278.3 CHF
Average target price
274 CHF
Spread / Average Target
  1. Stock Market
  2. Equities
  3. ROG Stock
  4. News Roche Holding AG
  5. Roche Holding: In line quarterly results won’t cut it for Roche